---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108859"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:07:51.719573+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026

## Summary
- Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.
- Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.
- Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.
- Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.
- ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025.

## SEC filing metadata
- accession: 0000950170-25-108859
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/0000950170-25-108859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/annx-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108859
- JSON: https://secwatch.observer/filing/0000950170-25-108859.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.